B
휴온스
243070KOSDAQ의약품 제조업56.0 / 100
Reference Date: 2026-04-13
Financial Score25.5 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure12.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but Operating Profit is on a declining trend. Slightly down 3.5% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Hoonswell, established in 1965, is a pharmaceutical company operating in specialty drugs, beauty & wellness, and contract manufacturing (CMO). Key products include local anesthetics, functional food supplements, and medical devices, with exports to the U.S. via FDA approval. The company expanded its global presence by launching its second plant in Cheongju in 2024.
Number of Employees
1,087people
Average Salary
58.0M KRW
Score Calculation Basis
Detailed Financial Score
PER
7.33Industry Average 14.808.0Point
Half of industry avg (excellent)
PBR
0.75Industry Average 1.045.5Point
Lower than industry avg (good)
ROE
11.04Industry Average 4.427.0Point
2.5x industry avg (excellent)
Debt Ratio
22.82Industry Average 11.980.5Point
1.9x industry avg (risky)
Trend 2023~20254.5 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲6.0% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼7.1% (2-year basis)
ROE Trend
2.5 / 4
Avg ROE 12.0% (declining, 3yr)
Detailed News Sentiment
9 totalPositive 0Neutral 4Negative 0Average Sentiment Score 50
- Neutral
- Neutral
- Neutral
Detailed Momentum
52-week position1.0Point
Near 52w low (18%, downtrend)
Current 25,850Won52-week high 32,05052-week low 24,400
1-month return2.0Point
1m -3.54% (slight drop)
Volume trend3.0Point
Volume flat
Detailed Disclosure
8 totalPositive 1Neutral 7Negative 0
- Positive배당락2026-04-01
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
- Neutral정기주주총회결과2026-03-31
- Neutral주식등의대량보유상황보고서(일반)2026-03-25
- Neutral감사보고서제출2026-03-23